What is the recommended management of menopausal vasomotor symptoms, including hormone therapy dosing, contraindications, non‑hormonal alternatives, and monitoring?

Management of Menopausal Vasomotor Symptoms

For symptomatic postmenopausal women under age 60 or within 10 years of menopause onset without contraindications, systemic hormone therapy is the most effective treatment, reducing vasomotor symptoms by approximately 75%. 1, 2, 3

Hormone Therapy Approach

First-Line Hormonal Treatment

For women with an intact uterus:

• Use combined estrogen plus progestogen to prevent endometrial hyperplasia and cancer 4, 5
• 17-beta estradiol is preferred over conjugated equine estrogens or ethinylestradiol 6
• Transdermal estradiol may be preferred over oral formulations due to lower rates of venous thromboembolism and stroke 5, 7
• Micronized progesterone is preferred over medroxyprogesterone acetate due to lower VTE and breast cancer risk 5

For women who have had a hysterectomy:

• Use estrogen alone, which has a more favorable risk/benefit profile 1, 5
• Estrogen-only therapy reduces breast cancer risk (8 fewer cases per 10,000 woman-years) 8

Dosing Strategy

• Use the lowest effective dose for symptom control 4
• Standard dosing: oral conjugated equine estrogen 0.625 mg/day or transdermal estradiol 50-100 mcg/day 6, 2
• Treatment duration should be based on persistent symptoms with periodic reevaluation, not arbitrarily stopped at age 65 9, 3

Absolute Risks and Benefits

With estrogen plus progestin therapy (per 10,000 women per year): 4, 10

• Harms: 7 additional CHD events, 8 more strokes, 8 more pulmonary emboli, 8 more invasive breast cancers
• Benefits: 6 fewer colorectal cancers, 5 fewer hip fractures

With estrogen-only therapy (per 10,000 woman-years): 8

• Harms: 11 more strokes, 7 more DVTs, 33 more gallbladder disease cases
• Benefits: 56 fewer fractures, 8 fewer breast cancers, 2 fewer deaths

Absolute Contraindications

Do not prescribe hormone therapy in women with: 7, 5

• History of hormone-dependent cancers (breast, endometrial)
• History of venous thromboembolism or stroke
• Active or recent thromboembolic event
• Coronary heart disease
• Active liver disease
• Unexplained vaginal bleeding
• Pregnancy
• Antiphospholipid antibody syndrome (especially thrombotic APS) 7

Non-Hormonal Alternatives

FDA-Approved and Evidence-Based Options

SSRIs/SNRIs (reduce symptoms by 40-65%): 11, 2, 12

• Paroxetine 7.5-12.5 mg/day (only FDA-approved non-hormonal option for VMS) 9
• Venlafaxine 37.5-75 mg/day 1, 11
• Citalopram 10-20 mg/day 11
• Escitalopram 10-20 mg/day 2
• Desvenlafaxine 50-100 mg/day 2

Important caveat: Paroxetine and fluoxetine should NOT be used in women taking tamoxifen due to CYP2D6 inhibition 1, 11

Other pharmacologic options: 1, 12

• Gabapentin 300-900 mg/day (reduces symptoms, safe with tamoxifen) 1, 5
• Fezolinetant (neurokinin-3 receptor antagonist) 12
• Oxybutynin 12
• Clonidine 0.1 mg/day (less effective; side effects include hypotension, dizziness, dry mouth) 1

Non-Pharmacologic Interventions

Recommended (Level I evidence): 12

• Cognitive-behavioral therapy
• Clinical hypnosis

May provide benefit: 1, 5

• Weight loss (≥10% body weight may eliminate hot flashes) 5
• Smoking cessation 5
• Stellate ganglion block 12

NOT recommended (insufficient evidence): 12

• Paced respiration
• Herbal supplements/phytoestrogens (including soy products, black cohosh) 4, 12
• Acupuncture
• Exercise specifically for VMS (though recommended for overall health) 5

Management of Genitourinary Syndrome of Menopause

Stepwise Approach 1, 5

Step 1: Non-hormonal first-line

• Vaginal lubricants for sexual activity 1, 5
• Vaginal moisturizers 3-5 times per week applied to vagina, vaginal opening, and external vulva 1

Step 2: Low-dose vaginal estrogen (if Step 1 fails)

• Vaginal estrogen cream, suppositories, or rings 5
• Provides 60-80% subjective improvement 2
• Systemic absorption is minimal; safe even in breast cancer survivors after discussion of risks/benefits 1, 5

Step 3: Alternative hormonal options

• Vaginal prasterone (DHEA) - 40-80% improvement 2
• Oral ospemifene 60 mg/day - 30-50% improvement 2

Step 4: For persistent introital pain

• Topical lidocaine for dyspareunia 1

Special Populations

Cancer Survivors

Breast cancer survivors: 5

• Hormone therapy is generally contraindicated 6
• Non-hormonal options (venlafaxine, gabapentin, CBT) are preferred 1, 5
• Low-dose vaginal estrogen may be considered after thorough risk/benefit discussion if conservative measures fail 1

Endometrial cancer survivors: 5

• Data suggest MHT is safe in early-stage disease 5
• Combined estrogen/progestogen may reduce disease reactivation risk 6

Non-hormone-sensitive cancers: 1

• Women under age 51 with treatment-induced menopause should be counseled to consider hormone therapy until average menopause age, then re-evaluate 1

Premature Ovarian Insufficiency (Age <40)

Treatment approach: 6

• Hormone replacement is indicated for symptom relief AND cardiovascular/bone protection
• Continue until at least age 51 (average menopause age) 6
• Hypertension is NOT a contraindication; use transdermal estradiol 6
• BRCA mutation carriers without personal breast cancer history may use HRT after prophylactic oophorectomy 6

Monitoring

Initial assessment: 5

• Check FSH, LH, estradiol, prolactin as clinically indicated
• Note: FSH is unreliable in women with prior chemotherapy, pelvic radiation, or on tamoxifen 5
• Pelvic examination for vaginal atrophy assessment 5

Ongoing monitoring: 6

• Annual clinical review focusing on compliance and symptom control 6
• No routine laboratory monitoring required unless prompted by specific symptoms 6
• Periodic reevaluation of benefits/risks for continuation 3

Agents NOT Recommended

• Custom-compounded bioidentical hormones (lack FDA approval and safety/efficacy data) 5, 13, 9
• Phytoestrogens/isoflavones for chronic disease prevention 4
• Hormone therapy for primary prevention of cardiovascular disease or chronic conditions in asymptomatic women 10, 13, 2